This was originally published in the Artificial Intelligencer newsletter, which is issued every Wednesday. Sign up here to learn about the latest breakthroughs in AI and tech.

ProKidney (PROK) presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with advanced CKD and diabetes. The ...